Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.71 USD | -2.47% | +0.68% | +25.66% |
Jun. 04 | Oppenheimer Raises Price Target on Crinetics Pharmaceuticals to $74 From $55, Maintains Outperform Rating | MT |
Jun. 03 | Transcript : Crinetics Pharmaceuticals, Inc. - Special Call |
Chart calendar Crinetics Pharmaceuticals, Inc.
Upcoming events on Crinetics Pharmaceuticals, Inc.
Past events on Crinetics Pharmaceuticals, Inc.
2024-06-07 11:00 am | Annual General Meeting |
2024-06-03 12:00 pm | Endocrine Society Meeting - Long-Term Safety |
2024-06-03 12:00 pm | Endocrine Society Meeting - Use of the Acromegaly |
2024-06-03 12:00 pm | Endocrine Society Meeting - Efficacy and Safety of Once-Daily |
2024-06-03 12:00 pm | Endocrine Society Meeting - Atumelnant |
2024-06-03 12:00 pm | Endocrine Society Meeting - Once Daily Oral Atumelnant |
2024-05-09 04:30 pm | Q1 2024 Earnings Call |
2024-05-09 04:05 pm | Q1 2024 Earnings Release |
2024-03-19 08:30 am | PATHFNDR 2 Phase 3 Study Results Call |
2024-03-12 04:30 pm | Paltusotine Phase 2 Study Results Call |
2024-02-28 04:30 pm | Q4 2023 Earnings Call |
2024-02-28 04:05 pm | Q4 2023 Earnings Release |
2024-01-09 06:45 pm | JPMorgan Healthcare Conference |
2023-12-18 05:00 pm | Business Update Call |
2023-11-30 08:00 am | Piper Sandler Healthcare Conference |
2023-11-28 03:50 pm | Evercore ISI HealthCONx Conference |
2023-11-07 04:05 pm | Q3 2023 Earnings Release |
2023-09-26 01:00 pm | Cantor Global Healthcare Conference |
2023-09-11 08:00 am | Paltusotine PATHFNDR-1 Phase 3 Study Results Call |
2023-08-08 12:00 pm | Investor Meeting - Key Opinion Leader |
Annual results
Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 1,19 1,03 15.68% | 0,07 0,09 -19.68% | 1,08 0,00 - | 4,74 4,32 9.73% | 4,01 4,21 -4.73% | 2,12 |
EBITDA Million USD | Released Forecast Spread | -52,9 -53,7 1.42% | -74,0 -68,7 -7.67% | -107 -106 -0.38% | -167 -167 0.04% | -222 -220 -0.58% | -296 |
EBIT Million USD | Released Forecast Spread | -53,8 -55,4 2.76% | -75,0 -73,4 -2.18% | -108 -106 -1.96% | -168 -166 -1.3% | -223 -216 -2.92% | -281 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -50,4 -52,3 3.52% | -73,8 -72,4 -1.88% | -108 -105 -2.07% | -164 -164 -0.22% | -209 -207 -1.34% | -256 |
Net income Million USD | Released Forecast Spread | -50,4 -52,2 3.41% | -73,8 -71,7 -2.96% | -108 -105 -2.74% | -164 -163 -0.59% | -215 -209 -2.77% | -266 |
EPS USD | Released Forecast Spread | -2,09 -2,16 3.36% | -2,42 -2,35 -2.93% | -2,80 -2,70 -3.64% | -3,15 -3,22 2.3% | -3,69 -3,58 -3.06% | -3,55 |
Announcement Date | 09/03/20 | 30/03/21 | 30/03/22 | 28/02/23 | 28/02/24 | - |
Quarterly results
Fiscal Period | December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 3,13 5,20 -39.79% | 0,44 0,72 -39.03% | 0,46 0,20 129% | 0,71 0,30 136.33% | 2,68 0,24 997.32% | 0,99 1,28 -22.8% | 0,35 0,14 145.15% | 0,00 0,18 - | 0,64 0,18 252% | 0,47 | 0,24 | 0,69 | 0,15 | 0,69 |
EBITDA Million USD | Released Forecast Spread | -33,6 -21,0 -59.94% | -42,8 -37,0 -15.76% | -43,2 -44,0 1.8% | -47,3 -47,0 -0.59% | -47,7 -49,0 2.66% | -62,4 -60,0 -3.99% | -73,1 -60,1 -21.61% | -72,9 | -70,0 | -70,6 | ||||
EBIT Million USD | Released Forecast Spread | -33,8 -28,0 -20.79% | -43,0 -35,6 -21% | -43,5 -44,6 2.47% | -47,6 -45,5 -4.5% | -48,0 -48,4 0.85% | -53,0 -47,5 -11.54% | -59,0 -51,0 -15.65% | -62,7 -55,1 -13.77% | -73,5 -62,4 -17.76% | -67,8 | -69,2 | -71,2 | -72,8 | -76,0 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -34,6 -27,8 -24.45% | -42,4 -34,5 -22.71% | -41,9 -43,7 4% | -45,0 -45,3 0.63% | -46,0 -47,5 3.11% | -51,0 -46,4 -9.88% | -57,5 -48,0 -19.59% | -55,9 -54,0 -3.46% | -66,5 -57,8 -14.95% | -63,4 | -64,9 | -66,8 | -69,2 | -72,5 |
Net income Million USD | Released Forecast Spread | -34,6 -28,1 -23.26% | -42,4 -34,0 -24.45% | -41,9 -42,6 1.54% | -45,0 -44,1 -1.95% | -46,0 -47,0 2.13% | -51,0 -47,5 -7.22% | -57,5 -49,3 -16.44% | -60,1 -54,8 -9.66% | -66,9 -59,0 -13.5% | -65,5 | -67,4 | -69,6 | -69,2 | -72,5 |
EPS USD | Released Forecast Spread | -0,73 -0,56 -29.55% | -0,81 -0,66 -23.51% | -0,78 -0,81 4% | -0,84 -0,83 -1.82% | -0,85 -0,84 -1.46% | -0,94 -0,86 -9.67% | -1,01 -0,86 -17.44% | -0,90 -0,88 -2.85% | -0,93 -0,80 -15.82% | -0,85 | -0,87 | -0,89 | -0,96 | -0,99 |
Announcement Date | 12/05/22 | 12/08/22 | 14/11/22 | 28/02/23 | 04/05/23 | 08/08/23 | 07/11/23 | 28/02/24 | 09/05/24 | - | - | - | - | - |
2024-07-15 01:45 am | ADDLIFE AB: Q2 2024 Earnings Release |
2024-07-21 | MEDPACE HOLDINGS, INC.: Q2 2024 Earnings Release (Projected) |
2024-07-23 | SYNGENE INTERNATIONAL LIMITED: Q1 2025 Earnings Release (Projected) |
2024-07-23 | ALKERMES PLC: Q2 2024 Earnings Release (Projected) |
2024-07-23 | IQVIA HOLDINGS INC.: Q2 2024 Earnings Release (Projected) |
2024-07-23 | ICON PUBLIC LIMITED COMPANY: Q2 2024 Earnings Release (Projected) |
2024-07-24 | LONZA GROUP AG: Q2 2024 Earnings Release |
2024-07-25 01:00 am | BACHEM HOLDING AG: Q2 2024 Earnings Release |
2024-07-25 | PHARVARIS N.V.: Q2 2024 Earnings Release (Projected) |
2024-07-26 01:00 am | BB BIOTECH AG: Q2 2024 Earnings Release |
Past sector events for Crinetics Pharmaceuticals, Inc.
2024-05-29 04:01 pm | IMMUNOVANT, INC.: Q4 2024 Earnings Release |
2024-05-23 07:00 am | CUREVAC N.V.: Q1 2024 Earnings Release |
2024-05-22 01:00 am | EVOTEC SE: Q1 2024 Earnings Release |
2024-05-21 05:14 pm | ALVOTECH: Q1 2024 Earnings Release |
2024-05-21 07:00 am | EXSCIENTIA PLC: Q1 2024 Earnings Release |
2024-05-17 02:00 am | BIOARCTIC AB: Q1 2024 Earnings Release |
2024-05-15 04:05 pm | CULLINAN THERAPEUTICS, INC.: Q1 2024 Earnings Release |
2024-05-15 07:00 am | PERSPECTIVE THERAPEUTICS, INC.: Q1 2024 Earnings Release |
2024-05-14 | GNI GROUP LTD.: Q1 2024 Earnings Release |
2024-05-14 04:05 pm | KYVERNA THERAPEUTICS, INC.: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- CRNX Stock
- Calendar Crinetics Pharmaceuticals, Inc.